A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation.

Trinh, Jonathan Q; Banskota, Shristi Upadhyay; Marr, Alissa S

Trinh, Jonathan Q; Banskota, Shristi Upadhyay; Marr, Alissa S.

Oncology (Williston Park) ; 38(6): 230-231, 2024 06 10.

Article in En | MEDLINE | ID: mdl-38899982

ABSTRACT

ABSTRACT

Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.

Subject(s)

Cyclin-Dependent Kinase Inhibitor p16; Mutation; Humans; Cyclin-Dependent Kinase Inhibitor p16/genetics; Cyclin-Dependent Kinase 4/genetics; Female; Skin Neoplasms/genetics; Skin Neoplasms/pathology; Skin Neoplasms/drug therapy; Middle Aged; Adenocarcinoma/genetics; Adenocarcinoma/drug therapy; Adenocarcinoma/pathology; Protein Kinase Inhibitors/therapeutic use; Cyclin-Dependent Kinase 6/genetics; Cyclin-Dependent Kinase 6/antagonists & inhibitors; Male; Pyridines/therapeutic use; Sweat Gland Neoplasms/genetics; Sweat Gland Neoplasms/pathology; Sweat Gland Neoplasms/drug therapy; Piperazines/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cyclin-Dependent Kinase Inhibitor p16 / Mutation Limits: Female / Humans / Male / Middle aged Language: En Journal: Oncology (Williston Park) Journal subject: NEOPLASIAS Year: 2024 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google